MX2020008377A - Marcadores de la enfermedad de farber y usos de estos. - Google Patents
Marcadores de la enfermedad de farber y usos de estos.Info
- Publication number
- MX2020008377A MX2020008377A MX2020008377A MX2020008377A MX2020008377A MX 2020008377 A MX2020008377 A MX 2020008377A MX 2020008377 A MX2020008377 A MX 2020008377A MX 2020008377 A MX2020008377 A MX 2020008377A MX 2020008377 A MX2020008377 A MX 2020008377A
- Authority
- MX
- Mexico
- Prior art keywords
- farber disease
- disease markers
- markers
- farber
- diagnosing
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01023—Ceramidase (3.5.1.23)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862648775P | 2018-03-27 | 2018-03-27 | |
| PCT/IB2019/000290 WO2019186272A1 (en) | 2018-03-27 | 2019-03-22 | Farber disease markers and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008377A true MX2020008377A (es) | 2020-09-25 |
Family
ID=66530353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008377A MX2020008377A (es) | 2018-03-27 | 2019-03-22 | Marcadores de la enfermedad de farber y usos de estos. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20190302126A1 (enExample) |
| EP (1) | EP3775924A1 (enExample) |
| JP (2) | JP2021516757A (enExample) |
| KR (2) | KR20240111011A (enExample) |
| CN (2) | CN111971562A (enExample) |
| AU (1) | AU2019244477A1 (enExample) |
| BR (1) | BR112020016435A2 (enExample) |
| CA (1) | CA3090354A1 (enExample) |
| CL (1) | CL2020002105A1 (enExample) |
| CO (1) | CO2020010043A2 (enExample) |
| IL (2) | IL311212A (enExample) |
| MX (1) | MX2020008377A (enExample) |
| PH (1) | PH12020551206A1 (enExample) |
| RU (1) | RU2020119065A (enExample) |
| SG (1) | SG11202007508TA (enExample) |
| WO (1) | WO2019186272A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220088158A1 (en) * | 2019-01-23 | 2022-03-24 | Aceragen, Inc. | Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase |
| CA3209730A1 (en) * | 2021-03-29 | 2022-10-06 | Alan Parker | Modified adenovirus |
| CN117647649A (zh) * | 2023-08-15 | 2024-03-05 | 迈健医药科技无锡有限公司 | 一种免疫细胞全维分析的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5059421A (en) | 1985-07-26 | 1991-10-22 | The Liposome Company, Inc. | Preparation of targeted liposome systems of a defined size distribution |
| US5631237A (en) | 1992-12-22 | 1997-05-20 | Dzau; Victor J. | Method for producing in vivo delivery of therapeutic agents via liposomes |
| CA2163860A1 (en) | 1993-06-30 | 1995-01-12 | Chung C. Hsu | Method for preparing liposomes |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5643599A (en) | 1995-06-07 | 1997-07-01 | President And Fellows Of Harvard College | Intracellular delivery of macromolecules |
| JP6832158B2 (ja) | 2013-03-14 | 2021-02-24 | アイカーン スクール オブ メディシン アット マウント サイナイ | 治療用酸性セラミダーゼ組成物ならびにそれを作製および使用する方法 |
| EP3115786A1 (en) * | 2015-07-08 | 2017-01-11 | Centogene AG | Method for the diagnosis of farber's disease |
-
2019
- 2019-03-22 IL IL311212A patent/IL311212A/en unknown
- 2019-03-22 MX MX2020008377A patent/MX2020008377A/es unknown
- 2019-03-22 CN CN201980008575.9A patent/CN111971562A/zh active Pending
- 2019-03-22 US US16/362,102 patent/US20190302126A1/en not_active Abandoned
- 2019-03-22 AU AU2019244477A patent/AU2019244477A1/en not_active Abandoned
- 2019-03-22 RU RU2020119065A patent/RU2020119065A/ru unknown
- 2019-03-22 JP JP2020543884A patent/JP2021516757A/ja active Pending
- 2019-03-22 WO PCT/IB2019/000290 patent/WO2019186272A1/en not_active Ceased
- 2019-03-22 KR KR1020247022597A patent/KR20240111011A/ko not_active Ceased
- 2019-03-22 EP EP19723847.0A patent/EP3775924A1/en not_active Withdrawn
- 2019-03-22 CA CA3090354A patent/CA3090354A1/en active Pending
- 2019-03-22 BR BR112020016435-6A patent/BR112020016435A2/pt unknown
- 2019-03-22 CN CN202311688835.6A patent/CN118112249A/zh active Pending
- 2019-03-22 KR KR1020207023065A patent/KR20200136367A/ko not_active Ceased
- 2019-03-22 SG SG11202007508TA patent/SG11202007508TA/en unknown
-
2020
- 2020-07-30 IL IL276420A patent/IL276420A/en unknown
- 2020-08-07 PH PH12020551206A patent/PH12020551206A1/en unknown
- 2020-08-14 CO CONC2020/0010043A patent/CO2020010043A2/es unknown
- 2020-08-14 CL CL2020002105A patent/CL2020002105A1/es unknown
-
2021
- 2021-03-08 US US17/195,240 patent/US20210199670A1/en not_active Abandoned
-
2023
- 2023-08-03 JP JP2023127159A patent/JP2023159164A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020016435A2 (pt) | 2020-12-15 |
| KR20200136367A (ko) | 2020-12-07 |
| CO2020010043A2 (es) | 2020-11-10 |
| RU2020119065A (ru) | 2022-04-27 |
| PH12020551206A1 (en) | 2021-04-19 |
| EP3775924A1 (en) | 2021-02-17 |
| CN111971562A (zh) | 2020-11-20 |
| SG11202007508TA (en) | 2020-09-29 |
| CL2020002105A1 (es) | 2020-12-04 |
| CN118112249A (zh) | 2024-05-31 |
| JP2021516757A (ja) | 2021-07-08 |
| US20190302126A1 (en) | 2019-10-03 |
| IL311212A (en) | 2024-05-01 |
| WO2019186272A1 (en) | 2019-10-03 |
| US20210199670A1 (en) | 2021-07-01 |
| AU2019244477A1 (en) | 2020-06-25 |
| CA3090354A1 (en) | 2019-10-03 |
| JP2023159164A (ja) | 2023-10-31 |
| KR20240111011A (ko) | 2024-07-16 |
| IL276420A (en) | 2020-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| NZ742787A (en) | Compositions comprising bacterial strains | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| MX378686B (es) | Composiciones que comprenden cepas bacterianas. | |
| PH12022550646A1 (en) | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use | |
| PH12018502020A1 (en) | Methods for treating and preventing c. difficile infection | |
| MX2020006297A (es) | Variantes de cd19. | |
| PH12021550413A1 (en) | Vitamin d pediatric dosage forms, methods of making and using | |
| AU2015249633A8 (en) | Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab | |
| MX2019008038A (es) | Composiciones y metodos para tratar la enfermedad de farber. | |
| MX2019012352A (es) | Composiciones, sistemas, kits y metodos para ablacion neural. | |
| MX2021003180A (es) | Métodos y kits para preparar sangre entera con inactivación de patógenos. | |
| MX388026B (es) | Compuestos y métodos para modular la tirosina cinasa de bruton. | |
| WO2017066712A3 (en) | Modulators of telomere disease | |
| WO2020209988A3 (en) | Diverse marker panel for ptsd diagnosis and treatment | |
| PH12020551206A1 (en) | Farber disease markers and uses thereof | |
| MX2020012990A (es) | Formulaciones de tegavivint y compuestos relacionados. | |
| MX2019010060A (es) | Composiciones y metodo para tratar cancer. | |
| MX2020007393A (es) | Compuestos de fósforo(n)amidatacetal y fosf(on)atalcetal. | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
| MX2022005358A (es) | Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso. | |
| WO2018144870A8 (en) | Compositions and methods for inhibiting reticulon 4 | |
| MX390050B (es) | Composiciones para el cuidado personal | |
| EP4283304A3 (en) | Methods of detecting anti-leptin neutralizing antibodies |